Provide-hf Study Results: Patient-reported Outcomes Investigation Following Initiation of Drug Therapy With Entresto (sacubitril/valsartan) in Heart Failure
Year: 2020
Type: article
Abstract: PARADIGM-HF showed that sacubitril/valsartan (sac/val) improved quality of life (QOL) vs enalapril in heart failure with reduced ejection fraction (HFrEF), yet limited data are available regarding QOL changes after sac/val initiation in routine practice.
PROVIDE-HF was a prospective study of HFrEF
Authors: Robert John Mentz, Haolin Xu, Emily Claire O'Brien, Laine Thomas, Tamas Alexy, Bhanu Gupta, Juan Vilaro, Anuradha (Anu) Lala, Ravi Dhingra, Alexandros Briasoulis, Marc A. Simon, Josef Stehlik, Jo Rodgers, Shannon Dunlay, Martha Abshire, Quinn Wells, Kurt G. Barringhaus, Peter Eckman, Brian Lowes, Johana Espinoza, Rosalia Blanco, Xian Shen, Carol Duffy, Adrian Hernandez
Institution: Duke University
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,000
OpenAlex ID: W3010705968